RXRX · ISSUER CIK 1601830
RECURSION PHARMACEUTICALS, INC.
Between Aug 1, 2026 and Oct 29, 2026, 7 RECURSION PHARMACEUTICALS, INC. insiders reported $0.00 of open-market purchases and $644K of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 5 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$644KInsider selling
−$644KNet open-market
Oct 7, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 202618:08 | Oct 6, 2026 | RXRX | Director | S · Sell10b5-1 | $4.84 | −50,000 | 6,108,287 | -1% | −$242K | ||
| Oct 7, 202618:08 | Oct 6, 2026 | RXRX | Director | S · Sell10b5-1 | $5.00 | −25,000 | 162,156 | -13% | −$125K | ||
| Oct 7, 202618:08 | Oct 6, 2026 | RXRX | Director | M · Exercise10b5-1 | $2.22 | +25,000 | 187,156 | +15% | $56K | ||
| Oct 2, 202618:17 | Oct 1, 2026 | RXRX | Director | A · Grant | — | +4,607 | 245,371 | +2% | — | ||
| Oct 2, 202618:17 | Oct 1, 2026 | RXRX | Director | A · Grant | — | +3,378 | 1,476,707 | +0% | — | ||
| Sep 16, 202617:52 | Sep 15, 2026 | RXRX | Chief Financial Officer | F · Tax | $3.41 | −5,396 | 1,071,462 | -1% | $18K | ||
| Sep 10, 202617:55 | Sep 8, 2026 | RXRX | CEO and President, Director | S · Sell10b5-1 | $3.52 | −22,408 | 2,072,890 | -1% | −$79K | ||
| Sep 2, 202618:01 | Sep 1, 2026 | RXRX | Director | S · Sell10b5-1 | $3.34 | −30,000 | 6,158,287 | -0% | −$100K | ||
| Aug 18, 202617:44 | Aug 17, 2026 | RXRX | CEO and President, Director | F · Tax | $3.16 | −80,498 | 2,095,298 | -4% | $254K | ||
| Aug 18, 202617:44 | Aug 17, 2026 | RXRX | Chief Scientific Officer | F · Tax | $3.16 | −26,657 | 1,043,837 | -2% | $84K | ||
| Aug 18, 202617:44 | Aug 17, 2026 | RXRX | Chief Financial Officer | F · Tax | $3.16 | −25,018 | 1,076,858 | -2% | $79K | ||
| Aug 6, 202617:09 | Aug 4, 2026 | RXRX | Director | S · Sell10b5-1 | $3.25 | −30,000 | 6,188,287 | -0% | −$98K |